Parkinson disease continues to ... therapies, potential disease-modifying strategies, biomarker refinement, and earlier diagnostic approaches. While major headlines often draw immediate attention, many ongoing studies may have an equal or greater impact on long-term treatment decision making. With a rapidly advancing research pipeline, it is challenging to narrow the field. Here, we highlight several of the most clinically meaningful ongoing Parkinson disease trials likely to ... Parkinson disease continues to evolve as an area of active investigation, with progress spanning symptomatic therapies, potential disease-modifying strategies, biomarker refinement, and earlier diagnostic approaches. While major headlines often draw immediate attention, many ongoing studies may have an equal or greater impact on long-term treatment decision making. With a rapidly advancing research pipeline, it is challenging to narrow the field. Here, we highlight several of the most clinically meaningful ongoing Parkinson disease trials likely to influence care as we move into 2026. As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Parkinson disease that may impact care. The ACTIVATE trial examines BIA 28-6156 for GBA-PD, assessing its impact on MDS-UPDRS scores and other clinical measures, with promising phase 1 safety data. Gene therapy with AB-1005 in the REGENERATE-PD trial shows potential for improving Parkinson's symptoms, with prior phase 1b results indicating successful putamen coverage. The agent, which showed promise in a phase 1 study, is currently being assessed in the phase 2 REGENERATE-PD trial (NCT06285643), an 87-patient cohort study with trial sites in Germany, Poland, the United Kingdom, and the United States. In this randomized, double-blind, surgery-controlled study, investigators will use change in normalized good ON time per Hauser Diary over an 18-month treatment period as the primary outcome.5 · Currently, there are no FDA-approved therapies for PD that offer the same mechanism and target as AB-1005 does.

Original title: “Previewing Parkinson Disease Pipeline: Emerging Trials to Watch in 2026 | NeurologyLive - Clinical Neurology News and Neurology Expert Insights”